May 8, 2020 / 6:26 PM / 22 days ago

BRIEF-NIH Clinical Trial Testing Antiviral Remdesivir Plus Anti-Inflammatory Drug Baricitinib For COVID-19 Begins

May 8 (Reuters) - NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES:

* NIH CLINICAL TRIAL TESTING ANTIVIRAL REMDESIVIR PLUS ANTI-INFLAMMATORY DRUG BARICITINIB FOR COVID-19 BEGINS

* NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) SAYS TRIAL IS NOW ENROLLING HOSPITALIZED ADULTS WITH COVID-19 IN THE UNITED STATES

* NIAID SAYS TRIAL IS EXPECTED TO OPEN AT APPROXIMATELY 100 U.S. AND INTERNATIONAL SITES

* NIAID SAYS INVESTIGATORS CURRENTLY ANTICIPATE ENROLLING MORE THAN 1,000 PARTICIPANTS IN TRIAL TESTING REMDESIVIR PLUS BARICITINIB FOR COVID-19

* NIAID SAYS INVESTIGATORS CURRENTLY ANTICIPATE ENROLLING MORE THAN 1,000 PARTICIPANTS IN TRIAL TESTING REMDESIVIR PLUS BARICITINIB FOR COVID-19 Source text: (bit.ly/2YSpbdM)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below